Comparative Pharmacology
Head-to-head clinical analysis: DANTRIUM versus RELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTRIUM versus RELA.
DANTRIUM vs RELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (RyR1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.
Adults: 250-350 mg orally 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life: 8.7-14.4 hours in adults; longer with hepatic dysfunction.
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Renal: ~65% as unchanged drug; biliary/fecal: ~15% as metabolites; remainder metabolized and eliminated via urine.
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant